GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » Earnings per Share (Diluted)

Neurizon Therapeutics (FRA:ECQ0) Earnings per Share (Diluted) : €-0.02 (TTM As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics Earnings per Share (Diluted)?

Neurizon Therapeutics's Earnings per Share (Diluted) for the six months ended in Dec. 2024 was €-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.02.

Neurizon Therapeutics's EPS (Basic) for the six months ended in Dec. 2024 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.02.

Neurizon Therapeutics's EPS without NRI for the six months ended in Dec. 2024 was €-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.02.

During the past 3 years, the average EPS without NRIGrowth Rate was -58.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -17.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.30% per year.

During the past 13 years, Neurizon Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 75.00% per year. The lowest was -138.60% per year. And the median was 22.15% per year.


Neurizon Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Neurizon Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics Earnings per Share (Diluted) Chart

Neurizon Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.01 -0.01

Neurizon Therapeutics Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - -0.01 -0.01

Competitive Comparison of Neurizon Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Neurizon Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurizon Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Neurizon Therapeutics's PE Ratio falls into.


;
;

Neurizon Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Neurizon Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2024 is calculated as

Diluted Earnings Per Share (A: Jun. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.733-0)/370.811
=-0.01

Neurizon Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (Q: Dec. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-4.403-0)/482.760
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Neurizon Therapeutics  (FRA:ECQ0) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Neurizon Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurizon Therapeutics Business Description

Traded in Other Exchanges
Address
96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines